Preliminary Success Unveiled: BioNTech Announces Favorable Results from Phase 1/2 Clinical Trials of Cancer Combatting Vaccine
BioNTech, the prominent developer of mRNA vaccines, has released preliminary results for its BNT211 vaccine, which combines two techniques: cell therapy using CAR-T cells to target the CLDN6 antigen found...